Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 1: Introductory Statements and Governance
1ISG-010
REAL-WORLD EVIDENCE OF HIGH-COST DRUGS FOR METASTATIC MELANOMA: EFFECTIVENESS, COMPLIANCE TO CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION
1ISG-009
AVOIDED COST STUDY OF DRUGS IN CLINICAL TRIALS AT A TERTIARY HOSPITAL
1ISG-008
FLAT DOSES OF ANTI-PD1: WHAT IS THE ECONOMIC IMPACT?
1ISG-007
PEMETREXED´S LESSON
1ISG-006
HEPATITIS C TREATMENT: COST AND EFFECTIVENESS
1ISG-005
A COST EFFECTIVE STRATEGY: SWITCHING FROM ONE TO TWO TABLETS, IN A ONCE-DAILY REGIMEN IN HIV PATIENTS
1ISG-004
ABSTRACT WITHDRAWN
1ISG-003
BIOSIMILAR GROWTH HORMONE: DEFINED DAILY DOSE IN AN ITALIAN DISTRICT AFTER THE REGIONAL TENDER
1ISG-002
BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD-LEVEL HOSPITAL
1ISG-001
HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS ONE YEAR AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRALS
1ISG-021
PROCEDURAL KITS WITH MEDICAL DEVICES FOR EYE SURGERY: OPTIMISATION STRATEGY
1ISG-018
EVALUATION OF THE ECONOMIC SUSTAINABILITY OF A ROBOTIC SYSTEM FOR CHEMOTHERAPY COMPOUNDING
1ISG-017
ANALYSIS OF PRESCRIBING QUALITY INDEX (PQI) IN HOSPITAL CARE AND STRATEGIES FOR IMPROVEMENT
1ISG-016
EVALUATION OF SUBSTITUTION AND SWITCH TO ETANERCEPT BIOSIMILAR AND RELATED COST SAVINGS
1ISG-015
MULTIPLE SCLEROSIS COMMITTEE: INCLUDING A PHARMACIST AS PART OF THE MULTIDISCIPLINARY TEAM
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
Follow Us